German Market Opening: UK Exporters Eye European Opportunity
Following Germany regulatory reforms on cannabis, UK-based producers and distributors are exploring export opportunities to one of Europe largest pharmaceutical markets.
Germany regulatory reforms covering cannabis access have opened what many in the UK medical cannabis sector consider to be the most significant European market opportunity of the decade. UK-based producers and distributors with existing Home Office export licences are positioning themselves to capture a share of a German market that industry forecasters project could be worth several billion euros annually within three years.
UK Export Licensing
UK cannabis producers wishing to export to Germany must hold a Schedule 2 export licence from the Home Office and ensure that receiving parties in Germany hold the appropriate import permits under German narcotics law. Products must meet EU Good Manufacturing Practice standards, as Germany requires GMP certification for all imported medicinal cannabis products regardless of their country of origin.
Competitive Landscape
- The Netherlands and Portugal currently dominate European medical cannabis supply, having established production infrastructure earlier
- UK producers entering the German market face competition from well-established Dutch and Portuguese operations
- Canadian producers with existing EU market relationships also represent significant competition
- UK producers argue that proximity and post-Brexit regulatory flexibility offer advantages
Industry Views
Several UK Cannabis Industry Council members attended a trade mission to Berlin, establishing initial conversations with German distributors, pharmacy chains, and specialist cannabis clinics. Early feedback suggested strong German interest in UK-produced whole-flower products with verifiable traceability documentation.
"Germany is a once-in-a-generation market opening. UK producers who are GMP-ready have a genuine opportunity to establish long-term commercial relationships."
